13F Pro

SEC Form 4 reporting owner

Gordon Carl L

Gordon Carl L has filed 17 Form 4 transactions reported between November 21, 2025 and September 21, 2026, as Director of Electra Therapeutics, Inc., Director of BlossomHill Therapeutics, Inc., Director of Scribe Therapeutics, Inc., Director of Compass Therapeutics, Inc. and Director of Keros Therapeutics, Inc..

Name as filed: GORDON CARL L

Open-market buys, 24 mo
$45.0M
4 lines
Open-market sales, 24 mo
None
reported
Companies
5
with Form 4 filings
Latest transaction
Sep 21, 2026
transaction date

Roles and reported holdings

  • ETRAElectra Therapeutics, Inc.
    Sep 21, 2026

    Director

    Held indirectly (latest line)1,758,279 sh as of Sep 21, 2026 · Form 4

    24 months: $20.0M bought

  • BLSMBlossomHill Therapeutics, Inc.
    Aug 6, 2026 – Aug 10, 2026

    Director

    Held indirectly (latest line)2,714,279 sh as of Aug 10, 2026 · Form 4

    24 months: $10.0M bought

  • SCTXScribe Therapeutics, Inc.
    Jul 23, 2026 – Jul 27, 2026

    Director

    Held indirectly (latest line)1,348,825 sh as of Jul 27, 2026 · Form 4

    24 months: $15.0M bought

  • CMPXCompass Therapeutics, Inc.
    Jan 2, 2026

    Director

    No common-stock holding reported on a purchase, sale, gift or withholding line.

  • KROSKeros Therapeutics, Inc.
    Nov 21, 2025

    Director

    No common-stock holding reported on a purchase, sale, gift or withholding line.

Transaction history

All 17 reported transactions, newest first. Every row links to the Form 4 on SEC EDGAR.

DateCompanyTypeSharesValueFiling
Sep 21, 2026ETRADirectorOpen-market purchaseCode P · indirectAlso reported by ORBIMED ADVISORS LLC1,000,000$15.0M@ $15.00Form 4
Sep 21, 2026ETRADirectorConversion of derivativeCode C · indirect758,279—Form 4
Sep 21, 2026ETRADirectorOpen-market purchaseCode P · indirectAlso reported by ORBIMED ADVISORS LLC333,333$5.0M@ $15.00Form 4
Sep 21, 2026ETRADirectorConversion of derivativeCode C · indirect1,703,314—Form 4
Sep 21, 2026ETRADirectorConversion of derivativeCode C · indirect1,087,934—Form 4
Sep 21, 2026ETRADirectorConversion of derivativeCode C · indirect2,002,310—Form 4
Aug 10, 2026BLSMDirectorOpen-market purchaseCode P · indirectAlso reported by ORBIMED ADVISORS LLC625,000$10.0M@ $16.00Form 4
Aug 10, 2026BLSMDirectorConversion of derivativeCode C · indirect1,049,283—Form 4
Aug 10, 2026BLSMDirectorConversion of derivativeCode C · indirect1,039,996—Form 4
Aug 6, 2026BLSMGrant or awardCode A · direct23,904—Form 4
Jul 27, 2026SCTXDirectorConversion of derivativeCode C · indirect2,065,672—Form 4
Jul 27, 2026SCTXDirectorOpen-market purchaseCode P · indirectAlso reported by ORBIMED ADVISORS LLC1,000,000$15.0M@ $15.00Form 4
Jul 27, 2026SCTXDirectorConversion of derivativeCode C · indirect348,825—Form 4
Jul 23, 2026SCTXGrant or awardCode A · direct14,725—Form 4
Jan 2, 2026CMPXDirectorGrant or awardCode A · direct90,000—Form 4
Nov 21, 2025KROSDirectorDisposition to issuerCode D · indirect74,465$1.3M@ $17.75Form 4
Nov 21, 2025KROSDirectorDisposition to issuerCode D · indirect140,057$2.5M@ $17.75Form 4

How this page is built

Every row comes from a Form 4 filed with the SEC, which officers, directors and holders of more than 10% of a company’s stock must file within two business days of a trade. Transactions are grouped by the reporting owner’s name as filed (spacing, capitals and punctuation ignored); two different people filing under an identical name would appear together, and one person filing under two spellings appears on two pages.

Open-market totals count code P purchases and code S sales over the last 24 months. The same trade reported on more than one filing is counted once; when another owner (for example a fund and its general partner) reports the identical trade, they are listed beside it. Holdings are the shares owned after the latest purchase, sale, gift or tax-withholding line, shown separately for direct and indirect ownership; an indirect figure is one holding line, not a total across every trust or entity.

This page describes what was filed with the SEC; it is not investment advice or a recommendation to buy or sell any security.